Michael Lutz, global manager of Cogenics, said: “Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards, thus expanding Cogenics’s offering to our growing global pharmaceutical customer base.”
Danny Ching, CEO of SinoGenoMax, said: “This strategic agreement between Cogenics and SinoGenoMax increases the genotyping services and geographical scope of both companies. SinoGenoMax provides genomics-based services to both domestic and international pharmaceutical companies and this partnership represents a significant opportunity for SinoGenoMax to widen its international spectrum.”